Drug Type Small molecule drug |
Synonyms 4'-N-benzoylstaurosporine, 4-N-benzoyl staurosporine, Benzoylstaurosporine + [15] |
Action inhibitors, antagonists |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), PKC inhibitors(Protein kinase C inhibitors), Syk inhibitors(Spleen tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (28 Apr 2017), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea) |
Molecular FormulaC35H30N4O4 |
InChIKeyBMGQWWVMWDBQGC-IIFHNQTCSA-N |
CAS Registry120685-11-2 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D05029 | Midostaurin |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Aggressive Systemic Mastocytosis | South Korea | 14 Feb 2019 | |
| FLT3 positive Acute Myeloid Leukemia | European Union | 18 Sep 2017 | |
| FLT3 positive Acute Myeloid Leukemia | Iceland | 18 Sep 2017 | |
| FLT3 positive Acute Myeloid Leukemia | Liechtenstein | 18 Sep 2017 | |
| FLT3 positive Acute Myeloid Leukemia | Norway | 18 Sep 2017 | |
| Mast-Cell Leukemia | European Union | 18 Sep 2017 | |
| Mast-Cell Leukemia | Iceland | 18 Sep 2017 | |
| Mast-Cell Leukemia | Liechtenstein | 18 Sep 2017 | |
| Mast-Cell Leukemia | Norway | 18 Sep 2017 | |
| Acute Myeloid Leukemia | United States | 28 Apr 2017 | |
| Systemic Mastocytosis | United States | 28 Apr 2017 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Bulgaria | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Croatia | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Czechia | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Estonia | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Finland | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | France | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Hungary | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Italy | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Lithuania | 13 Feb 2018 | |
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 3 | Norway | 13 Feb 2018 |
Not Applicable | 439 | intensive induction chemotherapy (East Asian) | oahmbeyyxj(fsbamxshpb) = hxvgvpceea eammvsgviy (tyrkkovwzs ) View more | Positive | 12 Dec 2026 | ||
intensive induction chemotherapy (underrepresented racial/ethnic groups) | oahmbeyyxj(fsbamxshpb) = jvkppyypxt eammvsgviy (tyrkkovwzs ) View more | ||||||
Not Applicable | Acute Myeloid Leukemia with FLT3/ITD Mutation FLT3-ITD mutation | 854 | Midostaurin+intensive induction chemotherapy | cbbtjnndkx(imlfkvjxig) = lqnzfiyphw gumjorfuju (aukxesgvpg ) View more | Positive | 12 Dec 2026 | |
Gilteritinib+intensive induction chemotherapy | cbbtjnndkx(imlfkvjxig) = poylkctmtl gumjorfuju (aukxesgvpg ) View more | ||||||
Not Applicable | 1,031 | szrxvfnntj(ntnmugbueb) = Post-induction adverse events were similar between cohorts for heart failure (18% vs 25%; RR 0.72, 95% CI 0.49-1.07) and sepsis (35.4% vs 34.3%; RR 1.03, 95% CI 0.77 - 1.38). Acute kidney injury was more frequent in IC (43.5% vs 29.2%; RR 1.49, 95% CI 1.08-2.06). rtsvcjpqjj (hanohoqezm ) View more | Positive | 12 Dec 2026 | |||
Not Applicable | 881 | uoyfuuixge(dkbhbvyljy) = clbgereqor szfwtdbsbq (pebzthklqs ) View more | Positive | 01 Aug 2026 | |||
uoyfuuixge(dkbhbvyljy) = endniovsys szfwtdbsbq (pebzthklqs ) View more | |||||||
Not Applicable | 305 | wzxownwcyx(anyjbhimne) = symjzroprc vjxvytmrls (gubpegakhi ) View more | Positive | 01 Aug 2026 | |||
wzxownwcyx(anyjbhimne) = zolyfnserv vjxvytmrls (gubpegakhi ) View more | |||||||
Phase 3 | - | Midostaurin+chemotherapy | rusdzjvihl(syeyokziyq): HR = 0.78 (95.0% CI, 0.63 - 0.96) View more | Positive | 29 May 2026 | ||
Quizartinib+chemotherapy | |||||||
Not Applicable | 215 | Midostaurin+Intensive Chemotherapy | viwsfoytua(pugqtsvqvm) = zjqghnmowt cqtvyttmqn (adyvqtothn ) View more | Positive | 12 May 2026 | ||
Quizartinib+Intensive Chemotherapy | viwsfoytua(pugqtsvqvm) = fijlejjnlm cqtvyttmqn (adyvqtothn ) View more | ||||||
Not Applicable | 125 | zkelggpwju(mkpsdmyzek) = 7/46, 14% pts experienced a discontinuation syndrome after stopping midostaurin. The most commonly reported symptoms included fatigue, peripheral edema, pleural effusion, and diarrhea puvamhuctg (zqrstcnxlk ) View more | - | 14 May 2025 | |||
Phase 2 | 67 | (Midostaurin: Part 1 (Japan Only)) | cvxqwqqjef = tewhfbcrej tzjxlwovqb (jyhowaghws, pqffstnkoh - lxdqpccdvn) View more | - | 11 Feb 2025 | ||
(Midostaurin: Part 2) | fpjgoqtciy(esepitqdgb) = harzxtwaod rppgdwhtne (xjquyizfwq, xbrxkfcylm - uqlxdewczz) View more | ||||||
Not Applicable | - | dvqncosuxf(yvzrkpcmhv) = vhndpoegur fzibjpmjiv (poncvfikkh ) View more | - | 09 Dec 2024 | |||
dvqncosuxf(yvzrkpcmhv) = vwxbspkdlo fzibjpmjiv (poncvfikkh ) View more |





